Buccal Misoprostol Tablet Composition for Fast Disintegration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing misoprostol formulations face issues with variable absorption, extended disintegration times, oral irritation, and degradation due to moisture, particularly in non-oral routes, leading to inconsistent bioavailability and increased adverse effects, especially when administered in fasting conditions.
Innovation Solution
A dispersible solid pharmaceutical composition comprising misoprostol or its salt, with a hardness of 6 to 10 kp, disintegrating in less than 60 seconds and dissolving over 80% in 15 minutes, designed for buccal administration, optimized for fasting conditions to minimize fragmentation and oral irritation, and reduce first-pass metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If misoprostol is formulated with higher hardness to withstand handling and packaging, then mechanical strength is improved, but disintegration time increases and absorption becomes slower
Solution Approach 1:
The tablet is segmented into multiple functional layers: a hard outer shell providing mechanical strength (6-10 kp hardness) and an inner core containing misoprostol with disintegrants. This segmentation allows the outer layer to protect against fragmentation during blister packaging while the inner layer rapidly disintegrates (within 60 seconds) to release the drug for buccal absorption.
2Reliability
If misoprostol is administered orally in fasting state to avoid first-pass metabolism, then bioavailability is improved, but oral irritation and adverse effects increase
Solution Approach 1:
The buccal mucosa serves as an intermediary absorption site between the oral cavity and systemic circulation. The tablet is designed for buccal placement where misoprostol absorbs directly through the buccal mucosa into systemic circulation, bypassing both first-pass metabolism (maintaining high bioavailability) and gastric irritation (reducing adverse effects). The buccal route acts as a mediator that achieves both goals simultaneously.
3Object-affected harmful factors
If misoprostol is administered orally with food to reduce side effects, then adverse effects are reduced, but absorption and bioavailability decrease
Solution Approach 1:
Instead of the conventional oral route where food affects absorption, this invention inverts the administration route to buccal. The buccal mucosa absorption pathway is independent of gastrointestinal food presence, allowing the tablet to be taken with or without food while maintaining consistent high bioavailability and minimizing side effects regardless of feeding state.
4Ease of manufacture
If misoprostol tablets are packaged in large bottles for dispensing, then packaging efficiency is improved, but moisture exposure increases and potency varies
Solution Approach 1:
The packaging is segmented into individual blister packs, each containing a single misoprostol tablet in its own moisture-proof compartment. This segmentation protects each tablet from moisture exposure during storage and handling, maintaining consistent potency. The blisters can be dispensed from larger containers, combining individual protection with efficient storage.
5Duration of action of moving object
If misoprostol is given buccally with extended disintegration time, then absorption may be prolonged, but fragments migrate and variability in absorption increases
Solution Approach 1:
The tablet incorporates disintegrants that trigger rapid disintegration (within 60 seconds) upon contact with buccal moisture. This preliminary action ensures the tablet breaks down completely and uniformly before the patient can move or swallow it, preventing fragment migration and ensuring consistent absorption. The rapid disintegration occurs automatically upon placement in the buccal cavity.
Data Source
AI summary
A dispersible solid pharmaceutical composition buccal dosage form is provided that results in a better pharmacokinetic profile in conjunction with a reduced incidence of adverse side effects and may be administered under fasting conditions. The buccal dosage form may include misoprostol or a pharmaceutically acceptable salt thereof, one or more disintegrants, lubricants, diluents, and optionally one or more other excipients (including but not limited or antioxidant, color, or flavor). The buccal dosage form may have a hardness of about 6 pK to about 10 pK, allows administration non-orally, namely buccally; disintegration or dispersion in less than about 60 seconds; and has a greater than about 80 percent dissolution at 15 minutes.